Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis

This study has been completed.
Sponsor:
Information provided by:
Juravinski Cancer Centre Foundation
ClinicalTrials.gov Identifier:
NCT00814359
First received: December 23, 2008
Last updated: January 19, 2011
Last verified: May 2009
  Purpose

Radiation treatment is very effective for treating cancers of the head and neck, however, during the course of treatment, it is common for patients to experience soreness of their mouth and throat due to the radiation. When radiation causes inflammation of the inside of the mouth, it is called 'mucositis'. There are several mouthwashes that are commonly used to prevent and treat mucositis, but none of these have been shown to be superior to another. This study is being conducted to see if using a combination of magic mouthwash and sucralfate is better than using a single mouthwash called benzydamine at decreasing the burden of mucositis.


Condition Intervention Phase
Head and Neck Cancer
Mucositis
Drug: Combination of Magic Mouthwash Plus Sucralfate
Drug: 0.15% Benzydamine HCl
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.

Resource links provided by NLM:


Further study details as provided by Juravinski Cancer Centre Foundation:

Primary Outcome Measures:
  • The severity of patient-reported symptoms of mucositis as determined by the change in Oral Mucositis Weekly Questionnaire - Head and Neck Cancer (OMWQ-HN) score from baseline to 6 weeks. [ Time Frame: Baseline to 6 weeks after the initiation of radiotherapy. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The severity of patient-reported symptoms of mucositis throughout the course radiotherapy as determined by the area under the curve for mean change in OMWQ-HN scores from baseline. [ Time Frame: Baseline to 10 weeks after initiating radiotherapy. ] [ Designated as safety issue: No ]
  • Incidence of WHO Grade 3 or 4 oral mucositis after 4 weeks of radiotherapy. [ Time Frame: 4 weeks after initiating radiotherapy ] [ Designated as safety issue: No ]

Enrollment: 67
Study Start Date: May 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Magic Mouthwash Plus Sucralfate Drug: Combination of Magic Mouthwash Plus Sucralfate

Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.

The concentration of the sucralfate suspension will be 1g/5ml.

Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.

Other Names:
  • Mucositis Mouthwash
  • Sulcrate
Active Comparator: Benzydamine HCl Drug: 0.15% Benzydamine HCl
Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
Other Name: Tantum

Detailed Description:

Sixty patients with head and neck cancer being treated with 6 or more weeks of radiotherapy, will be randomly assigned to receive either a combination of magic mouthwash (diphenhydramine, dexamethasone and nystatin) plus sucralfate or benzydamine. Patients randomized to receive magic mouthwash plus sucralfate will rinse first with 5ml of the magic mouthwash for 2 minutes then swallow, followed by rinsing with 5ml of the 1g/5ml sucralfate for 2 minutes before swallowing, 4 times daily. Patients randomized to receive 0.15% benzydamine HCl will be instructed to rinse with 15ml of the solution for 2 minutes before expectorating, 4 times daily. Patients will start the mouthwash regimens prior to the initiation of radiotherapy, and stop 2 weeks after the completion of radiotherapy.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven squamous cell carcinoma of the head and neck.
  • Receiving 6 or more weeks of external beam radiotherapy to a treatment volume that includes mucosal surfaces of the head and neck.

Exclusion Criteria:

  • Age less than 18 years
  • ECOG Performance Score 2 or higher
  • Patient is unable to understand the protocol and/or unable to provide informed consent
  • Patient is unable or unwilling to complete the questionnaires which are written in English.
  • Prior radiation to the head and neck region that would result in overlap of fields for the current study.
  • Plan to receive a radiation treatment volume that only includes the larynx and or hypopharynx with no planned treatment of locoregional lymph nodes.
  • Plan to receive a concurrent chemotherapy agent other than cisplatin.
  • Plan to receive other investigational agents (eg. panitumumab).
  • Investigational agent of any kind within 30 days prior to randomization.
  • Concurrent administration of any other experimental intervention given for the purpose of preventing oral mucositis.
  • History of allergic or hypersensitivity reactions to any of the possible agents to be administered in the study.
  • Patients who are pregnant or lactating.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00814359

Locations
Canada, Ontario
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2
Sponsors and Collaborators
Juravinski Cancer Centre Foundation
Investigators
Principal Investigator: Joda Kuk, MD Juravinski Cancer Centre
  More Information

Publications:

Responsible Party: Dr. Joda Kuk, Principal Investigator, Juravinski Cancer Centre
ClinicalTrials.gov Identifier: NCT00814359     History of Changes
Other Study ID Numbers: MUCOSA-PROTECT
Study First Received: December 23, 2008
Last Updated: January 19, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by Juravinski Cancer Centre Foundation:
mucositis
radiation
magic mouthwash
sucralfate
benzydamine
diphenhydramine
dexamethasone
nystatin

Additional relevant MeSH terms:
Head and Neck Neoplasms
Mucositis
Neoplasms by Site
Neoplasms
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Benzydamine
Sucralfate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Ulcer Agents
Gastrointestinal Agents

ClinicalTrials.gov processed this record on October 19, 2014